Atlas Healthcare Physicians, an independent physician association in Los Angeles and Orange counties, will now cover Cardio Diagnostics Holdings’ Epi+Gen CHD and PrecisionCHD tests. This expansion provides eligible members in managed care populations with access to physician-ordered blood tests for coronary heart disease risk assessment, diagnosis, and personalized treatment planning. The coverage requires prior authorization.
Cardio Diagnostics Holdings, an AI-powered precision cardiovascular medicine company, developed these tests to enhance cardiovascular disease prevention, detection, and and management. The company aims to make these processes more accessible, personalized, and precise through its proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine, referred to as “Core Technology.”
The Epi+Gen CHD test evaluates a patient’s three-year risk of experiencing a coronary heart disease event. This predictive capability allows for earlier intervention strategies based on individual risk profiles.
PrecisionCHD assists in diagnosing coronary heart disease and identifying its underlying molecular drivers. Understanding these drivers can lead to more targeted and effective treatment plans for patients.
Both Epi+Gen CHD and PrecisionCHD are noninvasive blood-based diagnostics. They do not require fasting or radiation exposure, which supports broader adoption within community healthcare networks. This ease of use can reduce barriers to testing and encourage more widespread use of precision cardiovascular medicine.
The company’s focus on noninvasive methods aligns with efforts to integrate advanced diagnostics into routine care without increasing patient burden. This approach could improve early detection rates and optimize patient outcomes by providing timely, actionable information to healthcare providers.
The expansion of coverage through Cardio Diagnostics Holdings and Atlas Healthcare Physicians represents a step towards broader integration of AI-powered diagnostic tools in managed care settings. This development could influence how cardiovascular risk is assessed and managed for a significant patient population.
Future developments will likely focus on the impact of this expanded coverage on patient outcomes and the broader adoption of precision cardiovascular medicine. Observers will watch for data on how these tests influence treatment decisions and disease progression within the covered populations.